First Week of ERAS March 20th Options Trading

The piece outlines option strategies on Erasca Inc (ERAS) with concrete metrics: a $7.50 put bid at $0.40 would net a $7.10 effective cost basis versus the $9.56 market price (strike ~22% below current) and is assessed a 76% chance to expire worthless, implying a 5.33% return (30.92% annualized) on the cash commitment. On the call side, a $10.00 call bid at $1.50 used in a covered-call generates a 20.29% return if assigned at the March 20 expiration (strike ~5% above current) with a 43% chance to expire worthless; implied vols are elevated (puts 124%, calls 135%) versus a 12-month trailing volatility of 95%.

Analysis

Market structure: The high implied vol (IV 124–135% vs 95% realized) signals concentrated demand for idiosyncratic hedging/leverage in ERAS and a stretched options premium that benefits option sellers and market-makers collecting theta. Retail/strategic buyers who want equity exposure benefit from selling cash‑secured puts ($7.50) to target an effective basis of $7.10 (≈26% below spot $9.56); downside is concentrated on holders of large long exposures if a binary clinical/regulatory event hits. Liquidity is likely thin — option spreads/IV skew indicate supply of short-dated premium > buyers of risk, so small flow moves IV materially.

Risk assessment: Tail risks are classic biotech binaries — negative trial readout, FDA setback, or an unexpected cash burn forcing a dilutive raise (probability low-to-moderate but P&L decisive). Immediate (days) risk is IV spike into the Mar 20 expiry; short-term (weeks/months) risk centers on announced catalysts/partnerships; long-term risk is balance‑sheet dilution across 2–12+ months. Hidden dependencies: asymmetric hedge costs if you get assigned (need cash) and heavy gamma for sellers approaching expiration; monitor borrow/lending costs and short interest.

Trade implications: For tactical yield, favor small, cash‑secured put sells at $7.50 Mar20 sized 0.5–2% portfolio (target basis $7.10, stop-loss if stock <6.00 or IV +20%); avoid buying ATM/OTM calls given rich IV — prefer buy‑write (buy at ~9.56, sell $10 Mar20) for a capped 20% near-term return. If directional bullish longer term, use calendar/debit spreads to buy time (buy 3–6M call, sell Mar20 call) to mitigate expensive near-term IV. Hedge sector beta by shorting 0.3–0.5x IBB or buying $IBB puts when establishing >1% ERAS exposure.

Contrarian angles: The market may be overpricing near-term downside while underweighting strategic acquirability or partnership optionality — if ERAS has nonpublic catalysts, a positive readout could collapse IV down >50% and punish short premium sellers who are short-vol. Conversely, consensus may underprice the dilution risk; selling premium without allocation limits risks painful assignment. Historical parallels (small biotechs pre-readout) show binary outcomes: if you sell theta, size small and avoid naked short volatility into binary events.

Key Decisions for Investors

• Sell cash‑secured ERAS Mar20 $7.50 puts (collect $0.40) sized to 0.5–2.0% of portfolio capital; target effective entry basis $7.10; close or roll if ERAS falls below $6.00, or if IV rises >20% from current levels.
• Establish a buy‑write: purchase ERAS up to 2% portfolio weight at or below $9.60 and sell Mar20 $10 calls for ~$1.50 to capture a ~20.3% capped return to expiry; if ERAS >$12 prior to expiry, buy back calls and roll out to avoid assignment.
• Avoid purchasing short‑dated ERAS calls outright (IV >130%); if long volatility is desired, use a 3–6 month calendar (buy 3–6M ATM call, sell Mar20 ATM call) to reduce near‑term IV premium exposure and cap premium paid.
• When net long exposure to ERAS >1%, hedge sector/systematic risk by shorting IBB ~0.3x exposure or buying IBB 1–2 month puts sized to offset 20–30% of biotech beta; reassess after any trial/press release within 48 hours.